NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
Press Release / October 14, 2025
Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress
Press Release / October 14, 2025
Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress
🌟 Welcome Susan Wierzbicki to our #QualityAssurance team as a Senior Auditor! 👏
With 20+ years in GCP audit management, compliance & vendor qualification, most recently at TKL Research, she brings deep expertise to #NSPharma. We’re thrilled to have you, Susan! 💙 https://x.com/NSPharmaInc/status/1987898435870032358/photo/1
We’re excited to join #CureDuchenne for a special community dinner in Chicago! 💙
This is a night for caregivers & families impacted by Duchenne and Becker to connect & find support together.
🗓️ Nov 8, 6–9 PM
📍 Chicago Prime Steakhouse.
RSVP: https://ow.ly/CJPY50XnBRz https://x.com/NSPharmaInc/status/1986811620069191923/photo/1
A huge thank you to everyone who visited our poster at #AANEM2025 and to MaraWood, Michelle Previtera & Denise Quigley for sharing their insights! 💙
Did you miss us? View the poster here: https://ow.ly/fiui50XnBKc
#Duchenne #RareDiseases #ExonSkipping https://x.com/NSPharmaInc/status/1986449197164314827/photo/1
🏔️ We’re proud to sponsor #HopeForGus and their #EverestToEndDuchenne trek!
This inspiring journey to the Everest Base Camp raises awareness & funds for DMD research, with each step symbolizing hope & determination. 💙
Learn more: https://everesttoendduchenne.org
#NSPharma https://x.com/NSPharmaInc/status/1986086846653235408/photo/1
Please join us in welcoming Marcel Bourgeois to #NSPharma as National Director!
With 15+ years in #PatientAccess, including leadership at Takeda, he’s launched programs & teams improving access for rare disease patients. Excited to have you aboard!
#NewHire https://x.com/NSPharmaInc/status/1985361947546534020/photo/1
We are conducting a Phase 2 #ClinicalTrial evaluating NS-229, an investigational JAK1 inhibitor, to learn more about potential new treatment options for adults with #EGPA.
See if you are eligible to join:
https://clinicaltrials.gov/study/NCT06046222#participation-criteria
#PatientRecruitment #NSPharma https://x.com/NSPharmaInc/status/1984260117773115792/photo/1
We’re proud to sponsor the Jett Foundation’s final 2025 Family Workshop in Norfolk, VA!
Join us on Saturday Nov 8 for a day of learning, connection & empowerment supporting the Duchenne community.
Register here: https://ow.ly/gSuH50Xif1a
#Duchenne #NSPharma #CommunitySupport https://x.com/NSPharmaInc/status/1983534797260575194/photo/1
